Navigation Links
PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM)
Date:8/17/2011

tical Industry, the DataLabs® EDC solution from Perceptive Informatics, a subsidiary of PAREXEL, was named in The International Business Awards as Distinguished Honoree in the category of "Best New Product or Service of the Year:  Computer Software – Software as a Service." This honor recognizes the Company's focus on innovation and continuous investment in the next generation of technologies to accelerate clinical development.

Winners and honorees of The International Business Awards, selected from over 3,000 entries received from organizations and individuals in more than 40 countries, were determined through two rounds of judging by close to 200 professionals worldwide.  More information about The International Business Awards can be found at www.stevieawards.com/iba.

For more information about PAREXEL, visit www.PAREXEL.com. For more information about Perceptive Informatics, visit www.perceptive.com.

About The Stevie AwardsStevie Awards are conferred in four programs: The American Business Awards, The International Business Awards, the Stevie Awards for Women in Business, and the Stevie Awards for Sales & Customer Service.  Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide.  Learn more about the Stevie Awards at www.stevieawards.com.

About PAREXEL InternationalPAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PAREXEL International to Present at Wells Fargo Healthcare Conference
2. Pfizer Inc. and PAREXEL International Corp. Sign Strategic Partnership Agreement to Advance Clinical Development
3. PAREXEL Reports Second Quarter Fiscal Year 2011 Financial Results
4. PAREXEL Announces Date of Second Quarter Fiscal Year 2011 Earnings Release and Conference Call
5. Edwin Rivera-Martinez, Former Chief of the FDA’s International Compliance Branch, Joins PAREXEL Consulting Strategic Compliance Team
6. PAREXEL Announces Date of First Quarter Fiscal Year 2011 Earnings Release and Conference Call
7. PAREXEL Issues Updated Financial And Operational Information
8. PAREXEL Consulting Releases New Study Data on Drug Development Timelines in Safety First Era
9. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
10. PAREXEL International to Present at Robert Baird 2009 Healthcare Conference
11. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2009 Earnings Release and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... and RARITAN, N.J. ... Development, LLC (Janssen) announced data from the Phase ... improvement in progression-free survival (PFS) with trabectedin (YONDELIS ... advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated ... chemotherapy regimen. SAR3007 is the largest randomized Phase ...
(Date:6/1/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/57b5qj/global_pdt ... "Global PDT Machine Industry Report 2014" report ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ,The Global PDT ... in-depth study on the current state of the ... overview of the industry including definitions, classifications, applications ...
(Date:6/1/2015)...  Boston-based Veritas Genetics is launching its mission ... personalized medicine and prevention to the forefront, allowing ... Beginning with its first product, a genetic screen ... Genetics is making its products affordable and accessible, ... genetic data which will be shared with the ...
(Date:6/1/2015)... , June 1, 2015 Esperance Pharmaceuticals ... trial of lead candidate EP-100 in ovarian cancer patients ... designed to seek and destroy cancer cells that overexpress ... receptors are over-expressed in a wide range of cancers. ... Phase II trial of EP-100 were presented at ...
Breaking Biology Technology:Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6Global PDT Machine Industry Report 2014 2Veritas Genetics To Advance Precision Medicine And Disease Prevention 2Veritas Genetics To Advance Precision Medicine And Disease Prevention 3Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3
... July 7 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,("China-Biotics", the "Company") (Nasdaq: CHBT ... , today provides,further updates on the Company,s bulk additive operation. , ... China-Biotics gained ... and the total number of bulk customers increased to 39 by the ...
... , ... that from a single platform, scientists can efficiently profile lead compounds in their own ... ... -- Promega Corporation has partnered with SignalChem Pharmaceuticals to launch a flexible and complete ...
... CLEVELAND , July 7 DATATRAK International, Inc. ... eClinical solutions for the clinical trials industry, today announced that ... approximately $0.53 per share with certain members of ... sold pursuant to the private placement are restricted securities and ...
Cached Biology Technology:China-Biotics Provides Further Updates on Qingpu New Facility 2China-Biotics Provides Further Updates on Qingpu New Facility 3Promega Now Offers Complete Solution for Profiling Kinase Inhibitor Compounds Against the Human Kinome 2DATATRAK Completes Sale of 357,857 Common Shares to Directors and Management 2DATATRAK Completes Sale of 357,857 Common Shares to Directors and Management 3
(Date:5/27/2015)... , May 27, 2015   ... medication safety systems and image documentation solutions ... of comprehensive, technologically-advanced automation solutions, is pleased ... integration. The Codonics® Safe Label System® (SLS), ... in conjunction with the Omnicell Anesthesia Workstation, ...
(Date:5/25/2015)... market for wearable technologies is considered to be in ... several trials and prototypes. The release of the Apple ... interest in wearables as well as accelerate sales of ... in turn will spur greater innovation from other players ... and distributors. Photo - http://photos.prnewswire.com/prnh/20150526/218287 ...
(Date:5/22/2015)... According to a new market ... Thermal, Emotion, Forensic), by Software (Middleware, Databases), by Hardware (Cameras, ... and Home) - Global Forecast to 2020", published by ... in 2015 to $6.19 Billion by 2020, at a ... data Tables and   43 Figures spread through 140 ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3
... the word "doctor" to mean "all-knowing," unfortunately, this will ... of medical professionals sometimes leads to devastating misdiagnoses that ... their patients. , But there is hope for better, ... technologies, and one Florida State University researcher is putting ...
... data for E7389 in the treatment of advanced, refractory ... E7389 is a synthetic analog of halichondrin B ... studies to have highly potent anti-cancer activity in vitro ... a type of marine sponge. , This study was ...
... shown that the immune-stimulating hormone known as interleukin-12 ... immune-system protein, as an experimental therapy for some ... to stimulate the immune system to attack certain ... sometimes used to treat melanoma, advanced kidney cancer ...
Cached Biology News:Making medicine 'smarter' 2Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer 2Study shows combination of immune substances to be safe 2
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Mfr ...
... Single Cell Whole Genome Amplification Kit ... random fragmentation of genomic DNA and ... to PCR-amplifiable library molecules flanked by ... by PCR amplification of the library ...
Rabbit Anti-Mouse Ym1 Polyclonal Antibody,...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
Biology Products: